Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases

Please find below a video abstract in which Professor Vincent Cottin summarises the safety data from the INBUILD trial.

Header - Navigation Icon

The INBUILD trial was supported by Boehringer Ingelheim International GmbH (BI). The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for development of this video abstract or the manuscript on which it was based. Elizabeth Ng and Wendy Morris of FleishmanHillard, London, UK, provided editorial assistance, which was contracted and funded by BI. BI was given the opportunity to review the video abstract and manuscript for medical and scientific accuracy as well as intellectual property considerations.